VF Hive editor Jon Kelly, Kristen Scholer and the Hive panel discuss the top five stories of the week in politics, technology and business. Tom Frank and Bess Levin kick off The Hive 5 with the first legislative victory of Donald Trump's presidency. They talk about the tax reform bill that, critics argue, will raise the deficit, harm the middle class, and only benefit corporations. Maya Kosoff covers the latest troubles for Uber. She and Nick Bilton discuss the recent ruling from the European Court of Justice that Uber is essentially a cab company, as opposed to a digital technology company. Bess Levin and T.A. Frank weigh in on Bernie Sanders' suggestion that the Republican tax bill will be completely re-written once the Democrats take over Congress in 2018. The panel discusses a possible Sanders run for president in 2020. Bilton and Kosoff return to report on Facebook, and how 2017 was a reckoning for the company. They talk about whether Mark Zuckerberg can pivot in 2018, or if the company will be broken up. Levin and Frank round out The Hive 5 with a discussion on the return of Anthony Scaramucci to the news. They bring up his criticisms of Steve Bannon at a recent holiday party, and whether he might be well-suited to star in his own reality show.

Share:
More In Politics
Skydio CEO On Russia-US Drone Collision
Adam Bry, co-founder and CEO of drone manufacturer Skydio, joined Cheddar News to discuss the company's latest funding round and the Russia-US drone collision.
Fed Set to Launch Digital Payments System Over the Summer
The Federal Reserve on Wednesday evening said its long-awaited digital payment system, the FedNow Service, will start operating in July. The service is designed to provide a national platform for financial institutions to settle payments in real-time and at lower cost. That could include large banks, payment processors, and the U.S. Treasury.
Long-Used US Abortion Pill Under Threat in Texas Lawsuit
A federal judge in Texas raised questions Wednesday about a Christian group's effort to overturn the decades-old U.S. approval of a leading abortion drug, in a case that could threaten the country's most common method for ending pregnancies.
Load More